Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson's disease experiencing mild wearing-off: A randomised, double-blind trial

Journal of Neural Transmission

Volumn 121, Issue 4, 2014, Pages 357-366

  Tolosa, Eduardo ^a   Hernández, Basilio ^b   Linazasoro, Gurutz ^c   López Lozano, Juan José ^d   Mir, Pablo ^e,f   Marey, José ^g   Kulisevsky, Jaime ^h  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Medical Affairs Department   (Spain)

^c Policlinica Gipuzkoa   (Spain)

^d HOSPITAL RUBER INTERNACIONAL   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^g UNIVERSITY OF A CORUÑA   (Spain)

^h HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Parkinson disease; Quick questionnaire; UPDRS; Wearing off

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CARBIDOPA; CATECHOLS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NITRILES; PARKINSON DISEASE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84898909198     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-013-1114-x     Document Type: Article

References (22)

1. Boiko AN, Batysheva TT, Minaeva NG et al (2008) Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial). Neurosci Behav Physiol 38:933-936
2. Brooks DJ (2008) Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective. Neuropsychiatr Dis Treat 4:39-47
3. Eggert K, Skogar O, Amar K et al (2010) Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility - an open-label, 6-week study. J Neural Transm 117:333-342
4. Fahn S (2005) Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 252(Suppl 4):IV37-IV42
5. Fahn S, Oakes D, Shoulson I et al (2004) Levodopa and the progression of Parkinson's disease. N Engl J Med 351:2498-2508
6. Fung VS, Herawati L, Wan Y (2009) Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone. Mov Disord 24:25-31
7. Gordin A, Kaakkola S, Teravainen H (2004) Clinical advantages of COMT inhibition with entacapone - a review. J Neural Transm 111:1343-1363
8. Hauser RA, Panisset M, Abbruzzese G et al (2009) Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Mov Disord 24:541-550
9. Larsen JP, Worm-Petersen J, Siden A et al (2003) The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease. Eur J Neurol 10:137-146
10. Martinez-Martin P, Tolosa E, Hernandez B et al (2008) Validation of the "QUICK" questionnaire-a tool for diagnosis of "wearing-off" in patients with Parkinson's disease. Mov Disord 23:830-836
11. Nutt JG, Woodward WR, Beckner RM et al (1994) Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44:913-919
12. Parkinson Study Group (1997) Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group. Ann Neurol 42:747-755
13. Piccini P, Brooks DJ, Korpela K et al (2000) The catechol-O- methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J Neurol Neurosurg Psychiatry 68:589-594
14. Reichmann H, Boas J, Macmahon D et al (2005) Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol Scand 111:21-28
15. Rinne UK, Larsen JP, Siden A et al (1998) Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 51:1309-1314
16. Ruottinen HM, Rinne UK (1998) COMT inhibition in the treatment of Parkinson's disease. J Neurol 245:P25-P34
17. Schrag A (2005) Entacapone in the treatment of Parkinson's disease. Lancet Neurol 4:366-370
18. Solla P, Cannas A, Marrosu F et al (2010) Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo). Neuropsychiatr Dis Treat 6:483-490
19. Stocchi F (2006) The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations. Expert Opin Pharmacother 7:1399-1407
20. Stocchi F, Jenner P, Obeso JA (2010a) When do levodopa motor fluctuations first appear in Parkinson's disease? Eur Neurol 63:257-266
21. Stocchi F, Rascol O, Kieburtz K et al (2010b) Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68:18-27
22. Yahr MD, Duvoisin RC, Schear MJ et al (1969) Treatment of parkinsonism with levodopa. Arch Neurol 21:343-354